Expanding Product Sales and Restructuring Channels through Sales Partnerships
First written in FY2016. 5 of 10 entries say "Advanced", first in FY2019-Q1. Latest entry: FY2025.
1 other company's latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「Kunming Baker Norton Pharmaceutical Sales Corporation Limited (China) 1 January 2025 Exclusive Chinese distribution rights for ARTZ Dispo, a joint-function treatment Contract term: From the date of execution of the agreement through 31 December 2029」
For ARTZ Dispo in China, an exclusive distribution agreement through 31 December 2029 was disclosed, dated 1 January 2025. - FY2022AdvancedAnnual report
「Kunming Baker Norton Pharmaceutical Sales Corporation Limited (China) 1 December 2021 Exclusive Chinese distribution rights for ARTZ Dispo, a joint-function treatment Contract term: From the date of execution of the agreement through 31 December 2024」
For ARTZ Dispo in China, a new exclusive distribution agreement for China was signed in December 2021 upon expiration of the previous agreement. - FY2022-Q2AdvancedAnnual report
「31 August 2021 Exclusive U.S. distribution rights for Gel-One, a joint-function treatment Contract term: 10 years from 25 January 2022 (effective date)」
For the exclusive U.S. distribution of Gel-One, a new 10-year agreement was signed with Zimmer Biomet Holdings, Inc. before the previous agreement expired. - FY2020-Q3RestatedAnnual report
「We will continue to promote information-provision activities for medical institutions with our sales partners to ensure appropriate use and safety, and will work steadily to penetrate the market.」
Measures to promote market penetration for Hernicore through information provision to medical institutions using sales partners have been continued. - FY2019-Q2AdvancedAnnual report
「KAKEN PHARMACEUTICAL CO.,LTD., our marketing partner, began selling Hernicore, the lumbar disc herniation treatment, on 1 August 2018. We will seek gradual market penetration while promoting appropriate use.」
Sales of Hernicore through sales partner Kaken Pharmaceutical began on 1 August 2018. - FY2019-Q1AdvancedAnnual report
「Hernicore, a treatment for lumbar disc herniation, will be launched by Kaken Pharmaceutical from 1 August 2018.」
A specific plan for expanding product sales through a sales partner was finalized, with Hernicore to be launched by Kaken Pharmaceutical. - FY2018-Q1RestatedAnnual report
「MukoUp, an endoscopic submucosal injection material, saw an increase in the Company's sales following advance shipments to the sales partner.」
Product sales expansion and shipment operations through sales partners have been continued. - FY2017-Q3RestatedAnnual report
「MukoUp, an endoscopic submucosal injection material, saw an increase in the Company's sales due in part to inventory build-up following the change in sales partner in April 2016.」
The sales increase for MukoUp resulting from channel operations and inventory build-up following the change in sales partner has been reiterated. - FY2017-Q1RestatedAnnual report
「MukoUp, an endoscopic submucosal injection material, saw an increase in the Company's sales due in part to inventory build-up following the change in sales partner in April 2016.」
The inventory build-up and sales increase following the change in sales partner have been reiterated. - FY2016First statedAnnual report
「Shipments increased following the change in sales partner in April 2016, and both the number of units delivered to medical institutions and the Company's sales increased.」
The previous sales agreement for MukoUp, an endoscopic submucosal injection material, expired, and an exclusive domestic distribution agreement was signed with Boston Scientific Japan in April 2016.